Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


COVID-19 vaccine: let’s be honest about serendipity in clinical trials

The views expressed in this letter are those of the author’s. If you would like to submit a letter to The Pharmaceutical Journal, please click here.

After the Pfizer/Moderna COVID-19 vaccine was announced to confer more than 90% effectiveness, the news of the University of Oxford and AstraZeneca’s vaccine seemed a bit flat. This vaccine has 70% efficacy, “on average”. One trial gave half a dose and then, one month later, a full dose. Dig a little deeper, and this regime was owing to a “dosing error”. The efficacy of the vaccine rose to 90%. A head of communications at AstraZeneca called this a “useful mistake” as this dosing regimen was not planned.

What does this say? Well, it particularly highlights the role of serendipity, but it also questions some of the fundamental ethical principles of clinical research, as announcements get made before close scrutiny of the data. It would appear that only a small number of (lower-aged) subjects received the half dose. Without making The Pharmaceutical Journal read like Private Eye, it would appear that key details will be glossed over in order to not stop a press release going out. There needs to be greater transparency and closer scrutiny of the data before we all start patting each other’s backs.

Dave Sharma, company director, Consilia Medica Ltd

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2021.20208662

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.